MGC Pharmaceuticals - Director/PDMR Shareholding
11/01/2024 09:54
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240111:nRSK3970Za&default-theme=true
RNS Number : 3970Z MGC Pharmaceuticals Limited 11 January 2024
MGC Pharmaceuticals Ltd.
PDMR Notification
11 January 2024
ASX, LSE: MXC
MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') wishes to advise that
the following Persons Discharging Managerial Responsibilities (PDMR) have
dealt with shares in MGC Pharma, and this notification is made in accordance
the UK Market Abuse Regulations.
The shares subject of this notice were issued to the PDMR's as part of their
working contracts and as consideration for services rendered in lieu of cash
payments
1 Details of the person discharging managerial responsibilities/person closely
associated
(a) Name Amir Polak
2 Reason for the notification
(a) Position Chief Pharmaceutical Development Officer
(b) Initial notification/amendment Initial
(c) If amendment: reason n/a
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
Full name of entity MGC Pharmaceuticals Limited
Legal Entity Identifier Code 213800HRE3FQJ6RK4H10
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; (iv) each place
where transactions have been conducted
(a) Description of the financial instrument, type of instrument Fully Paid Ordinary Shares
(b) Identification Code (ISIN) AU000000MXC6
(c) Nature of transaction Shares issued as part of their working contracts and as consideration for
services rendered in lieu of cash payments
(d) Currency Price Volume Total
AUD A$0.55 600,000 A$330,000
Aggregated information
AUD A$0.55 600,000 A$330,000
(e) Date of transaction 10 January 2024
(f) Place of transaction Outside a trading venue
1 Details of the person discharging managerial responsibilities/person closely
associated
(a) Name Sabina Suljakovic
2 Reason for the notification
(a) Position Vice President of Global Quality
(b) Initial notification/amendment Initial
(c) If amendment: reason n/a
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
Full name of entity MGC Pharmaceuticals Limited
Legal Entity Identifier Code 213800HRE3FQJ6RK4H10
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; (iv) each place
where transactions have been conducted
(a) Description of the financial instrument, type of instrument Fully Paid Ordinary Shares
(b) Identification Code (ISIN) AU000000MXC6
(c) Nature of transaction Shares issued as part of their working contracts and as consideration for
services rendered in lieu of cash payments
(d) Currency Price Volume Total
AUD A$0.55 17,000 A$9,350
Aggregated information
AUD A$0.55 17,000 A$9,350
(e) Date of transaction 10 January 2024
(f) Place of transaction Outside a trading venue
1 Details of the person discharging managerial responsibilities/person closely
associated
(a) Name Yair Tal
2 Reason for the notification
(a) Position Chief Information Security Officer
(b) Initial notification/amendment Initial
(c) If amendment: reason n/a
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
Full name of entity MGC Pharmaceuticals Limited
Legal Entity Identifier Code 213800HRE3FQJ6RK4H10
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; (iv) each place
where transactions have been conducted
(a) Description of the financial instrument, type of instrument Fully Paid Ordinary Shares
(b) Identification Code (ISIN) AU000000MXC6
(c) Nature of transaction Shares issued as part of their working contracts and as consideration for
services rendered in lieu of cash payments
(d) Currency Price Volume Total
AUD A$0.55 300,000 A$165,000
Aggregated information
AUD A$0.55 300,000 A$165,000
(e) Date of transaction 10 January 2024
(f) Place of transaction Outside a trading venue
1 Details of the person discharging managerial responsibilities/person closely
associated
(a) Name Yifat Steuer
2 Reason for the notification
(a) Position Chief Operating Officer and Deputy CEO
(b) Initial notification/amendment Initial
(c) If amendment: reason n/a
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
Full name of entity MGC Pharmaceuticals Limited
Legal Entity Identifier Code 213800HRE3FQJ6RK4H10
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; (iv) each place
where transactions have been conducted
(a) Description of the financial instrument, type of instrument Fully Paid Ordinary Shares
(b) Identification Code (ISIN) AU000000MXC6
(c) Nature of transaction Shares issued as part of their working contracts and as consideration for
services rendered in lieu of cash payments
(d) Currency Price Volume Total
AUD A$0.55 1,100,000 A$605,000
Aggregated information
AUD A$0.55 1,100,000 A$605,000
(e) Date of transaction 10 January 2024
(f) Place of transaction Outside a trading venue
1 Details of the person discharging managerial responsibilities/person closely
associated
(a) Name Rowan Harland
2 Reason for the notification
(a) Position Company Secretary
(b) Initial notification/amendment Initial
(c) If amendment: reason n/a
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
Full name of entity MGC Pharmaceuticals Limited
Legal Entity Identifier Code 213800HRE3FQJ6RK4H10
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; (iv) each place
where transactions have been conducted
(a) Description of the financial instrument, type of instrument Fully Paid Ordinary Shares
(b) Identification Code (ISIN) AU000000MXC6
(c) Nature of transaction Shares issued as part of their working contracts and as consideration for
services rendered in lieu of cash payments
(d) Currency Price Volume Total
AUD A$0.55 7,000 A$3,850
Aggregated information
AUD A$0.55 7,000 A$3,850
(e) Date of transaction 10 January 2024
(f) Place of transaction Outside a trading venue
1 Details of the person discharging managerial responsibilities/person closely
associated
(a) Name Ana Arhar Oblak
2 Reason for the notification
(a) Position Group Financial Controller
(b) Initial notification/amendment Initial
(c) If amendment: reason n/a
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
Full name of entity MGC Pharmaceuticals Limited
Legal Entity Identifier Code 213800HRE3FQJ6RK4H10
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; (iv) each place
where transactions have been conducted
(a) Description of the financial instrument, type of instrument Fully Paid Ordinary Shares
(b) Identification Code (ISIN) AU000000MXC6
(c) Nature of transaction Shares issued as part of their working contracts and as consideration for
services rendered in lieu of cash payments
(d) Currency Price Volume Total
AUD A$0.55 10,000 A$5,500
Aggregated information
AUD A$0.55 10,000 A$5,500
(e) Date of transaction 10 January 2024
(f) Place of transaction Outside a trading venue
-Ends-
Authorised for release by the Managing Director, for further information
please contact:
MGC Pharmaceuticals Ltd MGC Pharmaceuticals Ltd
Roby Zomer Rowan Harland
CEO & Managing Director Company Secretary
+61 8 6555 2950 +61 8 6555 2950
info@mgcpharma.co.uk (mailto:info@mgcpharma.co.uk) info@mgcpharma.co.uk (mailto:info@mgcpharma.co.uk)
UK IR/PR Advisers UK Brokers
IFC Advisory Oberon Capital
Graham Herring / Tim Metcalfe / Zach Cohen Aimee McCusker / Adam Pollock
+44 203 934 6630 +44 203 179 5300
mgcpharma@investor-focus.co.uk (mailto:mgcpharma@investor-focus.co.uk) aimeemccusker@oberoninvestments.com
(mailto:aimeemccusker@oberoninvestments.com) adampollock@oberoninvestments.com
(mailto:adampollock@oberoninvestments.com)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHKFLBFZFLEBBL
Recent news on Argent BioPharma
See all newsBrief: Argent Biopharma Enters Long Term Aquiol Licensing And Supply Agreement
Brief: Argent Biopharma Secures A$11M Financing Facility To Complete Strategic Acquisition
Brief: Argent Is Growing Through M&A Projected Merged Company Value Of $100M In Ac8 Asset Acquisition
Australia's Argent BioPharma set for best day in a year on AusCann deal
Brief: Argent Biopharma To Acquire Core Operating Assets And IP Portfolio Of Auscann Group